Shanghai Shen Lian Biomedical Corp Working Capital to Net Assets Ratio
Shanghai Shen Lian Biomedical Corp working capital to net assets ratio. Shanghai Shen Lian Biomedical Corp (688098) has a Working Capital to Net Assets ratio of 26.6% as of March 2026. Working capital of CN¥371.31 Million (current assets of CN¥495.15 Million minus current liabilities of CN¥123.85 Million) is measured against net assets of CN¥1.40 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shanghai Shen Lian Biomedical Corp (2013–2025)
Working capital to net assets ratio of Shanghai Shen Lian Biomedical Corp from 2013 to 2025. This chart shows how Shanghai Shen Lian Biomedical Corp's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 26.6%, reflecting working capital of CN¥371.31 Million against net assets of CN¥1.40 Billion CNY. See Shanghai Shen Lian Biomedical Corp (688098) defensive interval to measure how many days the company can operate on defensive assets alone.
Shanghai Shen Lian Biomedical Corp Working Capital to Net Assets Ratio by Year (2013–2025)
Shanghai Shen Lian Biomedical Corp working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Shen Lian Biomedical Corp from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Shanghai Shen Lian Biomedical Corp assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 28.8% | CN¥402.57 Million | CN¥1.40 Billion | CN¥535.90 Million | CN¥133.33 Million | ▼ -1.7 pp |
| 2024 | 30.5% | CN¥434.63 Million | CN¥1.43 Billion | CN¥550.83 Million | CN¥116.20 Million | ▼ -4.1 pp |
| 2023 | 34.6% | CN¥521.79 Million | CN¥1.51 Billion | CN¥598.29 Million | CN¥76.50 Million | ▼ -6.0 pp |
| 2022 | 40.6% | CN¥608.29 Million | CN¥1.50 Billion | CN¥705.50 Million | CN¥97.22 Million | ▼ -1.4 pp |
| 2021 | 42.1% | CN¥619.93 Million | CN¥1.47 Billion | CN¥733.46 Million | CN¥113.53 Million | ▼ -7.2 pp |
| 2020 | 49.3% | CN¥687.99 Million | CN¥1.40 Billion | CN¥793.86 Million | CN¥105.87 Million | ▼ -5.6 pp |
| 2019 | 54.9% | CN¥703.65 Million | CN¥1.28 Billion | CN¥849.98 Million | CN¥146.33 Million | ▲ +13.4 pp |
| 2018 | 41.6% | CN¥345.74 Million | CN¥831.94 Million | CN¥496.92 Million | CN¥151.18 Million | ▲ +11.6 pp |
| 2017 | 30.0% | CN¥164.70 Million | CN¥549.27 Million | CN¥283.61 Million | CN¥118.91 Million | ▲ +4.3 pp |
| 2016 | 25.7% | CN¥119.43 Million | CN¥465.47 Million | CN¥261.75 Million | CN¥142.32 Million | ▲ +0.6 pp |
| 2015 | 25.1% | CN¥79.60 Million | CN¥317.41 Million | CN¥252.50 Million | CN¥172.90 Million | ▲ +9.6 pp |
| 2014 | 15.5% | CN¥37.38 Million | CN¥241.57 Million | CN¥324.71 Million | CN¥287.32 Million | ▼ -28.6 pp |
| 2013 | 44.1% | CN¥144.55 Million | CN¥327.59 Million | CN¥348.49 Million | CN¥203.94 Million | — |